Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis allows generic sales in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties.

The agreement settles a three-year US patent infringement suit issued against generic manufacturers Barr Pharmaceuticals and Teva Pharmaceuticals. The agreement states that in exchange for royalties, Barr and Teva can sell cheaper versions of the allergy drugs Allegra and Nasacort in the US. Royalties are to be applied to sales retrospectively.

Under the terms of the agreement, Barr will have an option to purchase the finished pharmaceutical product from sanofi-aventis on a non-exclusive basis.

Sanofi-aventis is continuing with ongoing patent infringements suits against other generic manufacturers.

In 2007, US sales of Allegra and Nasacort totalled $276m and $301m, respectively.

19th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics